It was recently observed that glutamatergic activation of the infralimbic cortex by glutamate transporter-1 blockade or AMPA microinfusion reduced depression-like behavior by promoting serotonin release from the raphe nuclei in rats [29], which may partly explain how serotonin reuptake inhibitors reduce IFN-α-mediated depression [30]. Here, SLC1A2 is linked to depressive symptom measurement.